相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers
Alvaro Teijeira et al.
THERANOSTICS (2022)
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
Alexander Muik et al.
CANCER DISCOVERY (2022)
The Next Decade of Immune Checkpoint Therapy
Padmanee Sharma et al.
CANCER DISCOVERY (2021)
CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development
Kenji Hashimoto
CANCERS (2021)
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma
John Timmerman et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Approach to Patients with Eosinophilia
Fei Li Kuang
MEDICAL CLINICS OF NORTH AMERICA (2020)
Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity
Sun K. Ho et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
Kurt A. Schalper et al.
NATURE MEDICINE (2020)
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
Kobe C. Yuen et al.
NATURE MEDICINE (2020)
A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies
G. Ku et al.
ANNALS OF ONCOLOGY (2020)
T-cell agonists in cancer immunotherapy
Yeonjoo Choi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database
Quentin Scanvion et al.
ONCOIMMUNOLOGY (2020)
Checkpoint Inhibitor Pneumonitis: Too Clinically Serious For Benefit?
Tri Le et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343
Marlon J. Hinner et al.
CLINICAL CANCER RESEARCH (2019)
An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer
Dinh-Toi Chu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy
Christina Claus et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
Gerald P. Linette et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer
Rachel Howard et al.
SCIENTIFIC REPORTS (2019)
New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
Inaki Etxeberria et al.
ESMO OPEN (2019)
Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis
Qiang Su et al.
FRONTIERS IN IMMUNOLOGY (2019)
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Alyson Haslam et al.
JAMA NETWORK OPEN (2019)
Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer
Neil H. Segal et al.
CLINICAL CANCER RESEARCH (2018)
TGF-β Inhibition and Immunotherapy: Checkmate
Karuna Ganesh et al.
IMMUNITY (2018)
The promise and challenges of immune agonist antibody development in cancer
Patrick A. Mayes et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis
Ke Ma et al.
FRONTIERS IN PHARMACOLOGY (2018)
HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients' Response to Neoadjuvant Chemotherapy
Diana P. Saraiva et al.
FRONTIERS IN IMMUNOLOGY (2018)
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
Cariad Chester et al.
BLOOD (2018)
Phase 1 trial of RO6874813, a novel bispecific FAP-DR5 antibody, in patients with solid tumors
Johanna Bendell et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
Neil H. Segal et al.
CLINICAL CANCER RESEARCH (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment
Jason B. Williams et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors
Anthony W. Tolcher et al.
CLINICAL CANCER RESEARCH (2017)
Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma
M. Stroh et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
MultiQC: summarize analysis results for multiple tools and samples in a single report
Philip Ewels et al.
BIOINFORMATICS (2016)
FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling
Xuguang Yang et al.
CANCER RESEARCH (2016)
Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies
Arantza Azpilikueta et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Fitting Linear Mixed-Effects Models Using lme4
Douglas Bates et al.
JOURNAL OF STATISTICAL SOFTWARE (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
4-1 BB agonists: multi-potent potentiators of tumor immunity
Todd Bartkowiak et al.
FRONTIERS IN ONCOLOGY (2015)
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Yang Liao et al.
BIOINFORMATICS (2014)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
Difference Tracker ImageJ plugins for fully automated analysis of multiple axonal transport parameters
Simon Andrews et al.
JOURNAL OF NEUROSCIENCE METHODS (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Hypercostimulation through 4-1BB Distorts Homeostasis of Immune Cells
Seung-Woo Lee et al.
JOURNAL OF IMMUNOLOGY (2009)
Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
Michael C. Milone et al.
MOLECULAR THERAPY (2009)
Simultaneous inference in general parametric models
Torsten Hothorn et al.
BIOMETRICAL JOURNAL (2008)
Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients
C Kloft et al.
INVESTIGATIONAL NEW DRUGS (2004)
Functional CD137 receptors are expressed by eosinophils from patients with IgE-mediated allergic responses but not by eosinophils from patients with non-IgE-mediated eosinophilic disorders
IVWM Heinisch et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2001)
分享论文
